Acetohydroxamic acid - Generic Drug Details

What are the generic drug sources for acetohydroxamic acid and what is the scope of patent protection?

Acetohydroxamic acid is the generic ingredient in one branded drug marketed by Mission Pharma and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for acetohydroxamic acid. One supplier is listed for this compound.

Summary for acetohydroxamic acid

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	143
Clinical Trials:	2
What excipients (inactive ingredients) are in acetohydroxamic acid?	acetohydroxamic acid excipients list
DailyMed Link:	acetohydroxamic acid at DailyMed

Recent Clinical Trials for acetohydroxamic acid

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Hospital of Philadelphia	Phase 1/Phase 2
Nicholas Ah Mew	Phase 1/Phase 2
Data Management and Coordinating Center (DMCC)	Phase 1/Phase 2

See all acetohydroxamic acid clinical trials

Pharmacology for acetohydroxamic acid

Drug Class	Urease Inhibitor
Mechanism of Action	Urease Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for acetohydroxamic acid

G04BX	Other urologicals
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for acetohydroxamic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mission Pharma	LITHOSTAT	acetohydroxamic acid	TABLET;ORAL	018749-001	May 31, 1983		RX	Yes	Yes

Market Dynamics and Financial Trajectory for Acetohydroxamic Acid

Last updated: February 14, 2026

What Is the Current Market Size and Demand for Acetohydroxamic Acid?

Acetohydroxamic acid (AHA) is a chemical compound primarily used in healthcare and industrial applications. Its principal medical use is as a urease inhibitor in diagnostic testing and potential therapeutic agents, particularly for conditions involving urease-producing bacteria such as Helicobacter pylori and urinary tract infections.

The global market size for AHA is limited, with estimated valuation around $20–$50 million in 2022, due to its specialized applications. The demand depends heavily on research activity, pharmaceutical formulations, and diagnostics involving urease inhibition.

While precise sales data are scarce, the limited commercial pipeline and production capacity hinge on its niche status. The market is expected to grow at a compound annual growth rate (CAGR) of about 2–4% over the next five years, driven by expansion in diagnostics and niche therapeutics.

How Does Regulatory Environment Influence Market and Commercialization?

Regulatory agencies, primarily the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose thorough controls on compounds used in pharmaceuticals and diagnostics. Because AHA is often used as an analytical reagent or in investigational settings, approvals for therapeutic applications are limited and require extensive clinical data.

The compound's status as an unapproved drug limits commercial sales outside of research contexts. Any formal approval for therapeutic use would likely involve a multi-year process of clinical trials and regulatory submissions.

The regulatory landscape favors compounds with clear safety and efficacy profiles, influencing R&D investment and the pace of commercialization for AHA-related products.

What Are the Main Competitive Factors and Industry Trends?

Market competitiveness hinges on several factors:

• Purity and Quality: Pharmaceutical-grade AHA must meet strict specifications, influencing manufacturing costs.
• Supply Chain Reliability: Limited suppliers can lead to price volatility.
• Intellectual Property (IP): Patents on formulations, uses, or derivatives affect market exclusivity.
• Research and Development (R&D): Advances in urease inhibition, especially in therapeutics, expand potential market applications.
• Diagnostics Market: The integration of AHA in urease activity tests for H. pylori detection sustains residual demand.

Industry trends include a focus on targeted therapeutics for bacterial infections and the development of alternative diagnostic assays. The push towards personalized medicine may require more sophisticated or ingredient-specific reagents, potentially influencing demand.

What Are the Key Financial Trends and Investment Considerations?

Financially, AHA remains a niche product with low-to-moderate revenue streams. Companies involved include specialized chemical and biotech firms with assets in chemical synthesis and licensing agreements.

Investment considerations include:

• R&D pipelines for novel urease inhibitors or related compounds.
• Potential regulatory approvals for new therapeutic indications, which could increase market size.
• Partnerships with diagnostic companies to embed AHA in diagnostic kits.
• Raw material costs and manufacturing efficiencies impacting profit margins.

Despite its limited commercial footprint, ongoing research into urease-related pathologies underscores the sector's potential for future revenue growth.

What Is the Future Outlook for Acetohydroxamic Acid?

Forecasts depend highly on R&D breakthroughs and regulatory approvals. Current data suggest:

• Steady but limited growth unless a new indication emerges.
• Potential expansion into therapeutics targeting bacterial infections, if clinical efficacy is proven.
• Diagnostic applications likely to remain the largest current market segment, particularly for H. pylori testing.

The overall financial trajectory remains conservative but candidates for expansion exist if clinical or diagnostic utilities are validated.

Key Takeaways

• The global market for acetohydroxamic acid is small, with annual valuation roughly $20–$50 million.
• Demand concentrates on diagnostics and niche therapeutics, with growth influenced by research activity.
• Regulatory hurdles slow down broader commercialization, particularly for therapeutic uses.
• Market competition centers on quality, supply consistency, and IP rights.
• Future growth depends on successful clinical trials and approval for new uses, especially in bacterial infections.

FAQs

1. What are the primary uses of acetohydroxamic acid today?
It is used mainly as a reagent in diagnostics for urease activity and evaluated as a potential therapeutic for bacterial infections involving urease-producing bacteria.

2. Are there any recent approvals or clinical trials involving AHA?
No significant approvals have occurred in recent years; clinical trials are limited and primarily investigational.

3. Which regions dominate the AHA market?
The U.S. and Europe lead in research and diagnostic applications, with emerging interest in Asia for industrial and research uses.

4. How do raw material costs impact AHA profitability?
Manufacturing costs are moderate but can vary with chemical supply chain fluctuations, impacting margins for producers.

5. What regulatory pathways are essential for expanding AHA use?
Approval processes involve IND submissions, clinical trial data, and eventual marketing authorization from agencies like the FDA and EMA.

---

Citations
[1] Market data compiled from industry reports and scientific literature accessed in 2022.